Article Text

Download PDFPDF
Cost-effectiveness analysis
Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA

Statistics from Altmetric.com

Footnotes

  • Competing interests WAD has received unrestricted funding from Eli Lilly Australia to investigate the economic impact of weight change among patients with type 2 diabetes treated with antidiabetic agents.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.